AI Article Synopsis
- Nearly 50,000 deaths from colorectal cancer (CRC) occur annually in the U.S.; early detection through fecal immunochemical tests (FITs) can improve outcomes, especially in low-resource settings.
- The study involves 3,600 diverse participants aged 50-85 undergoing colonoscopy, who will complete five different FITs to evaluate their effectiveness in detecting advanced colorectal neoplasia (ACN).
- Findings will help identify the best FIT options for CRC screening, as these tests are affordable, require no preparation, and can be done privately at home, thereby potentially increasing screening rates and reducing CRC-related mortality.
Article Abstract
Background: There are nearly 50,000 colorectal cancer (CRC) deaths in the United States each year. CRC is curable if detected in its early stages. Fecal immunochemical tests (FITs) can detect precursor lesions and many can be analyzed at the point-of-care (POC) in physician offices. However, there are few data to guide test selection. Broader use of FITs could make CRC screening more accessible, especially in resource-poor settings.
Methods: A total of 3600 racially and ethnically diverse individuals aged 50 to 85 years having either a screening or surveillance colonoscopy will be recruited. Each participant will complete five FITs on a single stool sample. Test characteristics for each FIT for advanced colorectal neoplasia (ACN) will be calculated using colonoscopy as the gold standard.
Results: We have complete data from a total of 2990 individuals. Thirty percent are Latino and 5.3% are black/African American. We will present full results once the study is completed.
Conclusions: Our focus in this study is how well FITs detect ACN, using colonoscopy as the gold standard. Four of the five FITs being used are POC tests. Although FITs have been shown to have acceptable performance, there is little data to guide which ones have the best test characteristics and colonoscopy is the main CRC screening test used in the United States. Use of FITs will allow broader segments of the population to access CRC screening because these tests require no preparation, are inexpensive, and can be collected in the privacy of one's home. Increasing CRC screening uptake will reduce the burden of advanced adenomas and colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227954 | PMC |
| http://dx.doi.org/10.1016/j.cct.2021.106430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Healthcare is a major contributor to global greenhouse gas emissions. Colorectal cancer (CRC) screening is one of the most widely used healthcare services in the US, indicated for approximately 134 million adults. Recommended screening options include fecal immunochemical tests (FITs) every year, CT colonographies (CTCs) every 5 years, or colonoscopies every 10 years.
View Article and Find Full Text PDFGeneral Versus Interventional Gastroenterologists: A Comparative Analysis of Follow-Up Outcomes After Endoscopic Mucosal Resection of Colorectal Polyps.
Cureus
December 2024
Gastroenterology and Hepatology, Washington University in St. Louis, St. Louis, USA.
Introduction Colorectal cancer (CRC) represents a major global health burden, significantly impacting mortality rates and healthcare systems worldwide. CRC screening through colonoscopy enables early detection and removal of precancerous polyps. While standard polypectomy suffices for small polyps, larger ones require endoscopic mucosal resection (EMR).
View Article and Find Full Text PDFCaspase-4 Has Potential Utility as a Colorectal Tissue Biomarker for Dysplasia and Early-Stage Cancer.
Gastro Hep Adv
September 2024
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Background And Aims: Colorectal cancer (CRC) is the second most deadly cancer globally. The rapidly rising incidence rate of CRC, coupled with increased diagnoses in individuals <50 years, indicates that early detection of CRC, and those at an increased risk of CRC development, is paramount to improve the survival rates of these patients. Here, we profile caspase-4 expression across 2 distinct CRC development pathways, sporadic CRC (sCRC) and inflammatory bowel disease-associated CRC (IBD-CRC), to examine its utility as a novel biomarker for CRC risk and diagnosis.
View Article and Find Full Text PDFStandard operating procedure combined with comprehensive quality control system for multiple LC-MS platforms urinary proteomics.
Nat Commun
January 2025
School of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.
Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography-mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms.
View Article and Find Full Text PDF"Evaluating Current Diagnostic and Treatment Challenges in Colorectal Cancer: Strategies for improving care and outcomes in Georgia".
Cancer Treat Res Commun
January 2025
Caucasus Medical Centre, Tbilisi, Georgia; Ilia State University- School of Medicine. Tbilisi, Georgia. Electronic address:
Purpose: An initial analysis of population-based cancer survival data from Georgia revealed lower CRC survival rates compared to high-income countries. We conducted the study to address this issue and propose strategies for enhancing CRC care.
Patients And Methods: We analyzed CRC statistics, reviewed screening programs, and examined published CRC research in Georgia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!